Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Burke A. Cunha, Jeffrey Baron & Cheston B. Cunha. (2017) Once daily high dose tigecycline - pharmacokinetic/pharmacodynamic based dosing for optimal clinical effectiveness: dosing matters, revisited. Expert Review of Anti-infective Therapy 15:3, pages 257-267.
Read now
Read now
B.A. Cunha. (2011) Multidrug-Resistant Gram-Negative Bacilli Causing Urinary Tract Infections: Clinical Considerations. Journal of Chemotherapy 23:3, pages 171-174.
Read now
Read now
Mary L Townsend, Melanie W Pound & Richard H Drew. (2011) Potential role of tigecycline in the treatment of community-acquired bacterial pneumonia. Infection and Drug Resistance 4, pages 77-86.
Read now
Read now
David P Nicolau. (2009) Management of complicated infections in the era of antimicrobial resistance: the role of tigecycline. Expert Opinion on Pharmacotherapy 10:7, pages 1213-1222.
Read now
Read now
B.A. Cunha, B. Mcdermott & S. Nausheen. (2007) Single Daily High-Dose Tigecycline Therapy of a Multidrug-Resistant (MDR) Klebsiella pneumoniae and Enterobacter aerogenes Nosocomial Urinary Tract Infection. Journal of Chemotherapy 19:6, pages 753-754.
Read now
Read now
Articles from other publishers (12)
Chau Wei Ling, Kamal Sud, Rahul Patel, Gregory Peterson, Troy Wanandy, Siang Fei Yeoh, Connie Van & Ronald Castelino. (2023) Culture-directed antibiotics in peritoneal dialysis solutions: a systematic review focused on stability and compatibility. Journal of Nephrology.
Crossref
Crossref
Cheston B. Cunha & Steven M. Opal. 2020. Evidence-Based Practice of Critical Care. Evidence-Based Practice of Critical Care
291
298.e1
.
Jeffrey Baron, Shuntao Cai, Natalie Klein & Burke Cunha. (2018) Once Daily High Dose Tigecycline Is Optimal: Tigecycline PK/PD Parameters Predict Clinical Effectiveness. Journal of Clinical Medicine 7:3, pages 49.
Crossref
Crossref
P. R. Ingram, M. D. M. Rawlins, R. J. Murray, J. A. Roberts & L. Manning. (2016) Tigecycline use in the outpatient parenteral antibiotic therapy setting. European Journal of Clinical Microbiology & Infectious Diseases 35:10, pages 1673-1677.
Crossref
Crossref
M. Parsonage, S. Shah, P. Moss, H. Thaker, R. Meigh, A. Balaji, J. Elston & G. Barlow. (2009) Breakthrough bacteraemia with a susceptible Enterococcus faecalis during tigecycline monotherapy. Journal of Antimicrobial Chemotherapy 65:2, pages 370-374.
Crossref
Crossref
Burke A. Cunha. (2010)
Optimal Therapy for Multidrug-Resistant
Acinetobacter baumannii
. Emerging Infectious Diseases 16:1, pages 170-170.
Crossref
Crossref
E. Bouza. (2009) New therapeutic choices for infections caused by methicillin-resistant Staphylococcus aureus. Clinical Microbiology and Infection 15, pages 44-52.
Crossref
Crossref
Burke A. Cunha. 2009. Infectious Diseases in Critical Care Medicine. Infectious Diseases in Critical Care Medicine
288
294
.
Burke A. Cunha. 2009. Infectious Diseases in Critical Care Medicine. Infectious Diseases in Critical Care Medicine
288
294
.
Burke A. Cunha. (2009)
Pharmacokinetic Considerations regarding Tigecycline for Multidrug-Resistant (MDR)
Klebsiella pneumoniae
or MDR
Acinetobacter baumannii
Urosepsis
. Journal of Clinical Microbiology 47:5, pages 1613-1613.
Crossref
Crossref
Theodoros Kelesidis, Drosos E. Karageorgopoulos, Iosif Kelesidis & Matthew E. Falagas. (2008) Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. Journal of Antimicrobial Chemotherapy 62:5, pages 895-904.
Crossref
Crossref
Praveen K. Mullangi & George A. Pankey. (2008) Tigecycline in Critical Care. Critical Care Clinics 24:2, pages 365-375.
Crossref
Crossref